Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bausch Health Companies Inc T.BHC

Alternate Symbol(s):  BHC

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales... see more

TSX:BHC - Post Discussion

View:
Post by borderguy on Apr 08, 2024 12:26pm

BLCO spinoff

Seem like smaller shareholders of the parent company BHC are giving away the gem of the company. During the orginal IPO of BLCO that just over 11% was sold off at fire sell prices with no benifit to BHC or it's shareholder. As this was mostly a closed deal many of the existing shareholders were able to partake in purchasing shares in BLCO. The proper way to spinoff BLCO was through a warrent offer that could have been given to shareholders to allow then to partcipate in the future of both companies.
Comment by borderguy on Apr 08, 2024 12:59pm
At a ratio of .85 BLCO to BHC shares, a warrant to purchase .85 of a share of BLCO at $4 usd would net BHC over 1.2b usd for debt reduction. Warrants could have an expiry date for early 2025 and would automatically have a value of approximately $10 usd. Exercise price could be adjusted upward if more was needed for debt reduction but this would still allow the shareholders that bought into BHC a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities